Dipeptidyl peptidase-4 inhibitor treatment could decrease chronic rhinosinusitis in diabetic patients

doi:10.1093/qjmed/hcz250

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24624

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24624

题名:	Dipeptidyl peptidase-4 inhibitor treatment could decrease chronic rhinosinusitis in diabetic patients
作者:	Li, SY;Chen, HH;Lai, CC;Lin, CL;Kao, CH
日期:	2020
上传时间:	2022-08-09T08:05:23Z (UTC)
出版者:	OXFORD UNIV PRESS
ISSN:	1460-2725
摘要:	Aim: To evaluate the relationship between dipeptidyl peptidase-4 inhibitor (DPP4i) treatment and chronic rhinosinusitis (CRS) in diabetic patients. Methods: We used the Longitudinal Health Insurance Database for this population-based and population-matched cohort design study. Chi-square and Wilcoxon rank-sumtests were used to evaluate the association between categorical and continuous variables, respectively. The Kaplan-Meier method with the log-rank test was used to estimate the risk of CRS and DPP4i users. Results: A total of 6198 diabetic patients were included in this cohort study. DPP4i users had a lower risk of developing CRS. The risk of CRS was significantly lower in women, patients with a Diabetes Complications Severity Index score higher than 4, patients with comorbidities, and patients with higher cumulative defined daily dose in the DPP4i group. Conclusion: The results of our study demonstrate that the use of DPP4i treatment could decrease CRS risk in diabetic patients in Taiwan.
URI:	http://dx.doi.org/10.1093/qjmed/hcz250 https://www.webofscience.com/wos/woscc/full-record/WOS:000520433900005 https://ir.csmu.edu.tw:8080/handle/310902500/24624
關聯:	QJM-AN INTERNATIONAL JOURNAL OF MEDICINE ,2020 ,v113 ,issue 3 ,p181-185
显示于类别:	[中山醫學大學研究成果] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	191	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....